Kidney Transplant; Complications Clinical Trial
— GIPIKOfficial title:
Clinical Impact of the BioFire gastroIntestinal Panel for the Management of Diarrhea in Kidney Transplant Patients
This project focuses on the evaluation of the impact of the rapid mutltiplex test on changes in anti-infectious treatments in kidney transplant patients with diarrhea. A higher number of infectious agents detected on the same day of sampling could improve the etiological diagnosis of diarrhea in kidney transplant patients and optimize therapeutic management. A prospective study will be conducted to evaluate the impact of a rapid multiplex test with a wide panel of bacteria, viruses and parasites on the clinical management of kidney transplant patients with acute diarrhea. This impact will be evaluated using a control group of kidney transplant patients with acute diarrhea whose infectious diagnosis will be performed by standard methods. The main objective is to determine the impact of the rapid multiplex test on changes in anti-infectious treatments (initiation, change of molecule, total duration of treatment).
Status | Not yet recruiting |
Enrollment | 135 |
Est. completion date | September 2024 |
Est. primary completion date | September 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Age = 18 years - Informed consent - Patient who received a kidney transplant at least 3 months ago - Acute diarrhea (at least 3 unformed or liquid stools per day for at least 3 consecutive days or 3 per day and / or weight loss =2 kg and / or mucoid and / or bloody stool) or absence of diarrhea for at least a month (asymptomatic non randomized control group) - Affiliation to social security in accordance with the recommendations of the French law Exclusion Criteria: - Patients who received an identical HLA transplant from a related donor - Patients without health insurance - Patients under guardianship or curatorship - Pregnant (or breastfeeding) patient |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Assistance Publique - Hôpitaux de Paris |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Difference in the proportion of patients with anti-infectious treatment change | Difference in the proportion of patients with an adapation of anti-infectious treatment between the 2 randomized groups (rapid multiplex test group versus standard tests in patients with acute diarrhea) | 1 week | |
Primary | Difference in the time to anti-infectious treatment change | Difference in the time to an adaptation of anti-infectious treatment between the 2 randomized groups (rapid multiplex test group versus standard tests in patients with acute diarrhea) | 1 week | |
Secondary | Difference in the proportion of patients with an adaptation of immunosuppressive therapy | Difference in the proportion of patients with an adaptation of immunosuppressive therapy between the 2 randomized groups (rapid multiplex test group versus standard tests in patients with acute diarrhea) | 30 days | |
Secondary | Difference in the time to adaptation of immunosuppressive therapy | Difference in the time to adaptation of immunosuppressive therapy between the 2 randomized groups (rapid multiplex test group versus standard tests in patients with acute diarrhea) | 30 days | |
Secondary | Proportion of patients with additional tests for the etiological diagnosis of diarrhea | Difference in the proportion of patients with additional tests for the etiological diagnosis of diarrhea between the 2 randomized groups (rapid multiplex test group versus standard tests in patients with acute diarrhea) | 30 days | |
Secondary | Number of additional tests for the etiological diagnosis of diarrhea | Difference in the number additional tests for the etiological diagnosis of diarrhea between the 2 randomized groups (rapid multiplex test group versus standard tests in patients with acute diarrhea) | 30 days | |
Secondary | Time to digestive endoscopy | Difference in the time to digestive endoscopy between the 2 randomized groups (rapid multiplex test group versus standard tests in patients with acute diarrhea) | 30 days | |
Secondary | Duration of diarrhea | Difference in the duration of diarrhea between the 2 randomized groups (rapid multiplex test group versus standard tests in patients with acute diarrhea) | 30 days | |
Secondary | Proportion of patients with asymptomatic carriage of infectious agents | Proportion of patients with asymptomatic carriage of infectious agents in the asymptomatic control group | Day 1 | |
Secondary | Quantitative polymerase chain reaction (PCR) by multiplex PCR for infectious agents | Quantitative polymerase chain reaction (PCR) by multiplex PCR for infectious agents on a stool sample at baseline | Day 1 | |
Secondary | Alpha-diversity | Microbiota alpha-diversity on a stool sample at baseline | Day 1 | |
Secondary | Beta-diversity | Microbiota beta-diversity on a stool sample at baseline | Day 1 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04369456 -
Blood Biomarkers as Predictors of COVID-19 Disease Progression in Recently Infected Kidney Transplant Patients
|
N/A | |
Recruiting |
NCT06001320 -
De-novo Initiation of Letermovir vs Valganciclovir for Cytomegalovirus Prophylaxis in AA Kidney Trans Recip
|
Early Phase 1 | |
Withdrawn |
NCT04560582 -
Immunosuppression Reduction in Failed Allograft Guided by cfDNA
|
||
Not yet recruiting |
NCT05782543 -
Renal Ex Vivo Warm Advanced Resuscitation Through Machine Perfusion
|
N/A | |
Completed |
NCT03996551 -
ExeRTiOn2- The Weight Gain Prevention Exercise in Renal Transplant Online Study
|
N/A | |
Recruiting |
NCT05081141 -
HHV8 and Solid Organ Transplantation
|
||
Recruiting |
NCT04508907 -
A Study to Evaluate Preemptive Therapy in Hepatitis C (HCV) Organ Transplant Recipients
|
Phase 4 | |
Recruiting |
NCT06440330 -
Define Predictors for Posttransplant Diabetes Mellitus Study
|
||
Not yet recruiting |
NCT06025240 -
Expanding the Scope of Post-transplant HLA-specific Antibody Detection and Monitoring in Renal Transplant Recipients
|
||
Recruiting |
NCT04713774 -
Bone Density and Vascular Calcifications Evolution After Renal Transplant
|
||
Active, not recruiting |
NCT05483725 -
Immunological Safety and Effectiveness of the First Booster Dose of mRNA Vaccines Against COVID-19 in Kidney Transplant Recipients.
|
||
Recruiting |
NCT06095492 -
Effect of Empagliflozin vs Linagliptin on Glycemic Outcomes,Renal Outcomes & Body Composition in Renal Transplant Recipients With Diabetes Mellitus
|
N/A | |
Active, not recruiting |
NCT04207177 -
Immunosuppressive Drugs and Gut Microbiome: Pharmacokinetic- and Microbiome Diversity Effects
|
Phase 4 | |
Recruiting |
NCT03410654 -
Assessment of Cognitive Function Before and After Conversion From Immediate Release Tacrolimus to Envarsus XR.
|
Early Phase 1 | |
Completed |
NCT03373266 -
Serun Fluoride and Kidney Transplant
|
Phase 2 | |
Completed |
NCT04835948 -
Efficacy of Single Dose Anti-thymocyte Globulin in the Modulation of T Lymphocytes in Kidney Transplantation
|
||
Not yet recruiting |
NCT04514666 -
VOCs in Kidney and Liver Transplants
|
N/A | |
Recruiting |
NCT03373500 -
Effect of Dietary Salt Reduction on Blood Pressure in Kidney Transplant Recipients
|
N/A | |
Recruiting |
NCT05900401 -
Delayed Tolerance Through Mixed Chimerism
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT05166460 -
Novel Cooling Device for the Elimination of Warm Ischemia During Renal Transplantation
|
N/A |